Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00005841 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Toxicity/Side Effects

Conditions

Intraocular Melanoma
Melanoma (Skin)

Interventions

BIOLOGICAL: MART-1 antigen
BIOLOGICAL: gp100 antigen
BIOLOGICAL: incomplete Freund's adjuvant
BIOLOGICAL: progenipoietin
BIOLOGICAL: tyrosinase peptide

Sponsor

University of Southern California

Collaborators

[object Object]